Amylyx Pharmaceuticals (AMLX) Receivables - Other (2022 - 2026)
Amylyx Pharmaceuticals' (AMLX) quarterly Receivables - Other came in at $100000.0 in Q1 2026, little changed year-on-year from $100000.0 in Q1 2025, and little changed quarter-over-quarter from $100000.0 in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Receivables - Other (2022 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Receivables - Other history runs 5 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- On a quarterly basis, Receivables - Other changed 0.0% year-over-year to $100000.0 in Q1 2026; TTM through Mar 2026 was $100000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $100000.0, changed 0.0% from the prior year.
- Receivables - Other steadied at $100000.0 in Q1 2026 per AMLX's latest filing, from $100000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $800000.0 in Q2 2023 and bottomed at $100000.0 in Q3 2023.
- The 5-year median for Receivables - Other is $100000.0 (2023), against an average of $235714.3.
- Across the five-year window, Receivables - Other changed 0.0% in 2023 and slumped 87.5% in 2024, its largest moves.
- Year by year, Receivables - Other stood at $500000.0 in 2022, then changed by 0.0% to $500000.0 in 2023, then slumped by 80.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
- Per Business Quant, the three latest AMLX Receivables - Other figures stand at $100000.0 (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |